Cargando…

Factors Governing P-Glycoprotein-Mediated Drug–Drug Interactions at the Blood–Brain Barrier Measured with Positron Emission Tomography

[Image: see text] The adenosine triphosphate-binding cassette transporter P-glycoprotein (ABCB1/Abcb1a) restricts at the blood–brain barrier (BBB) brain distribution of many drugs. ABCB1 may be involved in drug–drug interactions (DDIs) at the BBB, which may lead to changes in brain distribution and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wanek, Thomas, Römermann, Kerstin, Mairinger, Severin, Stanek, Johann, Sauberer, Michael, Filip, Thomas, Traxl, Alexander, Kuntner, Claudia, Pahnke, Jens, Bauer, Florian, Erker, Thomas, Löscher, Wolfgang, Müller, Markus, Langer, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2015
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566129/ https://www.ncbi.nlm.nih.gov/pubmed/26202880 http://dx.doi.org/10.1021/acs.molpharmaceut.5b00168

Ejemplares similares

Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice
por: Hernández-Lozano, Irene, et al.
Publicado: (2021)

Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[(11)C]Methylpurine in Mice
por: Zoufal, Viktoria, et al.
Publicado: (2018)

Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling
por: Filip, Thomas, et al.
Publicado: (2021)

Small-animal PET evaluation of [(11)C]MC113 as a PET tracer for P-glycoprotein
por: Mairinger, Severin, et al.
Publicado: (2010)

Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model
por: Wanek, Thomas, et al.
Publicado: (2020)

Use of PET Imaging to Assess the Efficacy of Thiethylperazine to Stimulate Cerebral MRP1 Transport Activity in Wild-Type and APP/PS1-21 Mice
por: Wölfl-Duchek, Michael, et al.
Publicado: (2022)

Influence of Cation Transporters (OCTs and MATEs) on the Renal and Hepatobiliary Disposition of [(11)C]Metoclopramide in Mice
por: Hernández-Lozano, Irene, et al.
Publicado: (2021)

(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood–brain barrier, and not by MRP1 and BCRP
por: Römermann, Kerstin, et al.
Publicado: (2013)

Inhibition of breast cancer resistance protein at the murine blood-brain barrier by Ko143 studied with [(11)C]tariquidar and PET
por: Wanek, Thomas, et al.
Publicado: (2011)

Development and performance test of an online blood sampling system for determination of the arterial input function in rats
por: Roehrbacher, Friedrich, et al.
Publicado: (2015)

Using Positron Emission Tomography to Study Transporter-Mediated Drug–Drug Interactions in Tissues
por: Wulkersdorfer, B, et al.
Publicado: (2014)

Comparison of fully-automated radiosyntheses of [(11)C]erlotinib for preclinical and clinical use starting from in target produced [(11)C]CO(2) or [(11)C]CH(4)
por: Philippe, Cécile, et al.
Publicado: (2018)

Humanization of the Blood–Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus — Lessons from Three Unsuccessful Approaches
por: Krohn, Markus, et al.
Publicado: (2018)

Approaching complete inhibition of P-glycoprotein at the human blood–brain barrier: an (R)-[(11)C]verapamil PET study
por: Bauer, Martin, et al.
Publicado: (2015)

Drug-Induced Trafficking of P-Glycoprotein in Human Brain Capillary Endothelial Cells as Demonstrated by Exposure to Mitomycin C
por: Noack, Andreas, et al.
Publicado: (2014)

Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood–brain barriers studied with (R)-[(11)C]verapamil positron emission tomography
por: Müllauer, Julia, et al.
Publicado: (2012)

Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography
por: Bauer, Martin, et al.
Publicado: (2017)

Cross‐Isotopic Bioorthogonal Tools as Molecular Twins for Radiotheranostic Applications
por: Rosecker, Veronika, et al.
Publicado: (2019)

Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice
por: Biali, Myriam El, et al.
Publicado: (2023)

A face-to-face comparison of claudin-5 transduced human brain endothelial (hCMEC/D3) cells with porcine brain endothelial cells as blood–brain barrier models for drug transport studies
por: Gericke, Birthe, et al.
Publicado: (2020)

Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B
por: Hampel, Philip, et al.
Publicado: (2018)

Drug trapping in hERG K(+) channels: (not) a matter of drug size?
por: Linder, Tobias, et al.
Publicado: (2016)

A PET microdosing study with the P-glycoprotein inhibitor tariquidar
por: Bauer, Martin, et al.
Publicado: (2012)

In vivo characterization of [(18)F]AVT-011 as a radiotracer for PET imaging of multidrug resistance
por: Kannan, Pavitra, et al.
Publicado: (2019)

Imaging P‐Glycoprotein Function at the Blood–Brain Barrier as a Determinant of the Variability in Response to Central Nervous System Drugs
por: Bauer, Martin, et al.
Publicado: (2019)

Dose-response assessment of tariquidar for inhibition of P-glycoprotein at the human blood-brain barrier using (R)-[(11)C]verapamil PET
por: Bauer, Martin, et al.
Publicado: (2010)

BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo
por: Füreder, Thorsten, et al.
Publicado: (2010)

Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood–Brain Barrier
por: Bauer, M, et al.
Publicado: (2016)

Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography
por: Hernández Lozano, Irene, et al.
Publicado: (2019)

Factors That Limit Positron Emission Tomography Imaging of P-Glycoprotein Density at the Blood–Brain Barrier
por: Kannan, Pavitra, et al.
Publicado: (2013)

P-glycoprotein transporter in drug development
por: Prachayasittikul, Veda, et al.
Publicado: (2016)

Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy
por: Löscher, Wolfgang
Publicado: (2021)

Unravelling the complex drug–drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein
por: Ledwitch, Kaitlyn V., et al.
Publicado: (2016)

Application of Positron Emission Tomography in Drug Development
por: Bhattacharyya, Sibaprasad
Publicado: (2012)

Novel Intrinsic Mechanisms of Active Drug Extrusion at the Blood-Brain Barrier: Potential Targets for Enhancing Drug Delivery to the Brain?
por: Löscher, Wolfgang, et al.
Publicado: (2020)

Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
por: van der Pol, Karel H., et al.
Publicado: (2023)

P-glycoprotein Inhibition for Optimal Drug Delivery
por: Amin, Md. Lutful
Publicado: (2013)

Advances in oligonucleotide drug delivery
por: Roberts, Thomas C., et al.
Publicado: (2020)

Study Models of Drug–Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels
por: Veiga-Matos, Jéssica, et al.
Publicado: (2023)

A Novel Huntington’s Disease Assessment Platform to Support Future Drug Discovery and Development
por: Wu, Jingyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gruaj5tqd6oplfh3q5einmc1q8